Presenilin-2 Mutation Causes Early Amyloid  Accumulation and Memory Impairment in a Transgenic  Mouse Model of Alzheimer's Disease by Toda, Toshihiko et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 617974, 12 pages
doi:10.1155/2011/617974
Research Article
Presenilin-2Mutation Causes Early Amyloid
Accumulation and Memory Impairmentin a Transgenic
Mouse Model of Alzheimer’sDisease
Toshihiko Toda,1,2 YoshihiroNoda,1 GenzoIto,3 Masahiro Maeda,3 and Takahiko Shimizu1
1Molecular Gerontology, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-Cho, Itabashi-Ku, Tokyo 173-0015, Japan
2JAC Co, Ltd, 1-2-7 Higashiyama, Meguro-Ku, Tokyo 153-0043, Japan
3Immuno-Biological Laboratories Co, Ltd., 1091-1 Naka, Aza-Higashida, Fujioka-shi, Gunma 370-0831, Japan
Correspondence should be addressed to Takahiko Shimizu, shimizut@tmig.or.jp
Received 15 September 2010; Revised 17 November 2010; Accepted 4 December 2010
Academic Editor: Monica Fedele
Copyright © 2011 Toshihiko Toda et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
In order to clarify the pathophysiological role of presenilin-2 (PS2) carrying the Volga German Kindred mutation (N141I) in a
conventional mouse model of Alzheimer’s disease (AD) expressing amyloid precursor protein (APP) with the Swedish mutation
(Tg2576line),wegeneratedadoubletransgenicmouse(PS2Tg2576)bycrossbreedingthePS2mutantwithTg2576mice.Here,we
demonstrate that the PS2 mutation induced the early deposition of amyloid β-protein (Aβ) at 2-3 months of age and progressive
accumulation at 4-5 months of age in the brains of the mutant mice. The PS2 mutation also accelerated learning and memory
impairment associated with Aβ accumulation at 4-5 months of age in Tg2576 mice. These results suggest that the PS2 mutation
causes early cerebral amyloid accumulation and memory dysfunction. PS2Tg2576 mice are a suitable mouse model for studying
amyloid-lowering therapies.
1.Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder involving memory dysfunction that is characterized
by cerebral amyloid accumulation, which is observed as
senile plaques consisting of amyloid β-proteins (Aβ) ending
at the Ala42 or Val40 residues (Aβ42 and Aβ40, resp.)
[1]. Although robust Aβ deposition was observed in the
postmortem brains of critical AD patients with hippocampal
atrophy, the pathological relationship between memory
impairment and amyloid pathologies remains unclear. Aβ
is produced from β-amyloid precursor protein (APP) by
two proteases, β-a n dγ-secretases [2, 3]. Mutations in the
genes for APP or two homologous genes, presenilin-1 and -2
(PS1andPS2),whichproducecomponentsoftheγ-secretase
complex are linked to familial Alzheimer’s disease (FAD)
[4, 5]. FAD represents a small percentage (about 5%) of AD
cases, but the pathology of this disease arises at an unusually
youngage,asearlyasthethirddecadeoflife,andsoistermed
early-onset AD.
To understand the pathophysiological relationship bet-
ween amyloidosis and memory impairment in AD in order
to develop eﬀective therapies and preventative measures
(reviews [6, 7]), FAD-linked mutations in APP have been
produced in mice to provide AD mouse models, such as
PDAPP [8], Tg2576 [9], APP23 [10], and TgCRND8 mice
[11]. These mice typically demonstrate diﬀuse deposition
of amyloid plaques with dystrophic neurites, in addition to
inﬂammatory responses in microgliosis and astroglioses, but
no neuroﬁbrillary tangle pathology. The Tg2576 mouse line,
whichexpressestheprionpromoter-drivenhumanAPPwith
the Swedish mutation (APPswe, Lys670Asn, and Met671Leu)
has been utilized as a model for AD analyses [9]. Tg2576
mice showed impaired spatial learning and memory in the
Morris water maze at 6 months of age [12], when amyloid
deposition was not observed in their brain. Typical neuritic
plaques appeared in Tg2576 mice brain at 7-8 months of age
[9].
Many FAD pathologic mutations have been reported
in the PS1 gene, and transgenic mouse models have been2 Journal of Biomedicine and Biotechnology
produced by crossbreeding with APP mutant mice to clarify
the pathological role of the PS1 mutation on APP mutant
mice, such as PS1Tg2576 [13]. Gordon et al. reported
that the PS1 mutation accelerated AD-like pathologies with
increased Aβ42 production through enhanced γ-secretase
activity in PS1 (Met146Leu) and Tg2576 double transgenic
mice (PS1Tg2576) [13]. In contrast, the FAD-linked muta-
tions found in the PS2 gene have been well characterized,
including Asn141Ile (N141I, Volga German Kindred type)
[14]a n dM e t 239Val (M239V, Italian FAD type) [15]. These
PS2 mutations also enhance γ-secretase activity, leading to
increased Aβ42 production [16].
In the present study, to clarify the pathophysiological
role of the PS2 (N141I) mutation on amyloid formation
and memory function in Tg2576 mice, we generated double
transgenic mice (PS2Tg2576) by crossbreeding a PS2 mutant
with Tg2576 mice. We show the early onset of AD-like
phenotypes in PS2Tg2576 mice compared to Tg2576 mice.
2.MaterialsandMethods
2.1. Mice. Tg2576 mice (Tg(APPSWE)2576Kha), which
express human β-amyloid precursor proteins (hAPP) con-
taining the K670N and M671L mutations, which are known
as the Swedish type mutation (APPswe), coupled with
hamster prion promoter on a 129S6.Cg background were
purchased from Taconic Laboratories [9]. PS2M1 mice,
which express human presenilin-2 (PS2) proteins containing
the N141I mutation on a C57BL/6JJcl background, were also
used [17] .T h eP S 2t r a n s g e n ei se x p r e s s e du n d e rc o n t r o lo fa
ubiquitous CAGGS promoter consisting of cytomegalovirus
early enhancer coupled with chicken β-actin promoter. We
crossbred a Tg2576 male mouse with PS2 female mice
using in vitro fertilization and embryo transfer techniques
to generate PS2Tg2576 double transgenic mice born on the
same day.
The mouse genotyping was performed using the poly-
merasechainreaction(PCR)method.Tailtipsweredissolved
in 700μL of 0.05N NaOH for 45min at 95◦C and then
suspendedin60μLof1MTris-HCl,pH8.0.Thesuspensions
were centrifuged at 20, 400×gf o r1 0m i na t4 ◦C (MX-100,
TOMY) The resultant supernatants were collected and used
as DNA templates. The primers for PS2M1 (5 -CGG CTC
TAG AGC CTC TGC TAA C-3  and 5 -CTC TGT GTA GAA
GCG CAC AGA C-3 ) and Tg2576 (5 -CTG ACC ACT CGA
CCA GGT TCT GGG T-3  and 5 -GTG GAT AAC CCC
TCC CCC AGC CTA GAC CA-3 ) were used to identify each
transgenic allele. PCR was performed using the following
conditions: 1 cycle of 94◦C for 2min; 35 cycles of 98◦Cf o r
10sec, 60◦C for 30sec, and 72◦Cf o r1m i n ;a n d1c y c l eo f
72◦C for 5min.
All analyses were performed using ﬁrst generation
(129B6F1) mice at 2 to 11 months of age, and there were
four genotypes: wild type, PS2, Tg2576, and PS2Tg2576.
Therewereapproximatelyequalnumbersofmaleandfemale
mice. All experiments were performed by examiners blinded
to the genotypes of the mice. The animals were housed
under a 12-hour light/dark cycle and were allowedad libitum
access to food and water. The mice were maintained and
studied according to the protocols approved by the Animal
Care Committee of the Tokyo Metropolitan Institute of
Gerontology.
2.2. Immunohistochemistry. Mouse brains were collected at
eachtimepoint(2-3,4-5,6-7,and10-11monthsofage)after
anesthesia and perfusion. The removed brains were split into
twohemispheres,andthenonewasfrozeninliquidnitrogen.
The other hemisphere was ﬁxed in 4% paraformaldehyde
and embedded in paraﬃn for the immunohistochemical
study. The resultant sections (5μm) were deparaﬃnized,
rehydrated, and washed in phosphate buﬀered saline (PBS),
before being treated brieﬂy with formic acid for 5min and
washed in running water for 15min in the case of Aβ
staining. After incubation for 30min in 0.1% hydrogen
peroxide in methanol to prevent endogenous peroxidation,
the sections were washed in PBS-T (PBS containing 0.1%
Tween-20) and blocked with 10% normal goat serum in
PBS, before being incubated with an anti-Aβ antibody
(0.5μg/mL 82E1, Aβ42 and Aβ40, resp., IBL) for 1 hour
at room temperature. Then, the sections were incubated
with biotinylated secondary antibody for 30min at room
temperature. Immunoreactivity was visualized using an ABC
Elite kit according to the manufacturer’s protocol and the
sections were then stained for 5–7min with 0.2mg/mL
diaminobenzidine and 0.1% hydrogen peroxide in 10mM
Tris-HCl (pH 7.5). The sections were counterstained with
Meier ’s hematoxylin (Wako).
2.3. Speciﬁc Enzyme-Linked Immunosorbent Assay (ELISA)
for Aβ. Mouse brain tissue (0.1-0.2g) was homogenized
in 3 volumes (w/v) of TBS (50mM Tris-HCl (pH 7.6)
containing 150mM NaCl supplemented with 0.7mg/mL
pepstatin A, 1mM phenylmethylsulfonyl ﬂuoride, and cock-
tails of protease and phosphatase inhibitors (Complete Mini
and PhosSTOP, Roche Diagnostics). The homogenates were
centrifuged at 55,000×gf o r6 0m i na t4 ◦C using an Optima
TL ultracentrifuge and a TLA-55 rotor (Beckman Coulter)
to give the supernatant (S-55) and pellet (P-55) fractions.
The S-55 fraction was centrifuged at 100,000×gf o r3 0m i n
at 4◦C, and then the supernatant was collected as a TBS-
soluble fraction. The P-55 fraction was then dissolved by
sonication in an equal volume (v/v) of 6M guanidine-HCl
(Sigma) containing a mixture of protease inhibitors (Roche
Diagnostics), followed by centrifugation at 100,000×gf o r
30min at 4◦C. The supernatant was diluted in a 12-times
volume(v/v)ofTBStogenerateaguanidine-solublefraction.
The guanidine-soluble fraction was then centrifuged at
20,400×gf o r1 0 m i na t4 ◦C, and the supernatant was
collected as a TBS-insoluble fraction. The total protein
concentration of the fractions was determined using the DC
protein assay kit (Bio-rad), according to the manufacturer’s
protocol. The amounts of Aβ42 and Aβ40 in the TBS-
soluble and TBS-insoluble fractions were determined using
a sandwich EIA kit (No. 27712 for Aβ42 and 27714 for Aβ40,
IBL), according to the manufacturer’s instructions. The no.
27712 kit exclusively detects only human Aβ42, while theJournal of Biomedicine and Biotechnology 3
no. 27714 kit mainly detects human Aβ40 but partially reacts
with rodent Aβ40.
2.4. Water Maze. All behavior experiments were performed
longitudinally. The water maze pool (Muromachi Kikai),
which had a diameter of 120cm, contained opaque water (22
± 2◦C) with a platform (10cm in diameter) that had been
submerged 1.5cm below the surface. The hidden platform
task took 4 days to perform (4 sessions per day, at least 1
hour apart). The platform location remained constant, and
the entry points were changed semirandomly between trials.
One day after day 4 of the hidden platform task, a 2-minute
probe trial was carried out without the platform. The entry
pointfortheprobetrialswasthequadrantoppositethetarget
quadrant. Performance was monitored with the CompACT
VAS/DV video-tracking system (Muromachi Kikai).
2.5. Western Blotting. Mouse brain tissue (approximately
0.2g) was homogenized in 5 volumes (w/v) of RIPA buﬀer
(25mM Tris-HCl (pH 7.5) containing 150mM NaCl, 1%
NP-40, 1% sodium deoxycholate, and 0.1% sodium dodecyl
sulfate) supplemented with 0.7mg/mL pepstatin A, 1mM
phenylmethylsulfonyl ﬂuoride, and a mixture of protease
andphosphataseinhibitors(RocheDiagnostics).Theprotein
concentrations of the brain homogenates were determined
using the DC protein assay kit, before they were diluted to
1mg/mL with EzApply solution (ATTO), according to the
manufacturer’s instructions.
The proteins (10 or 20μg/well) were subjected to a
10%–20% gradient Tris-tricine gel (Novex, Invitrogen)
and transferred to a PVDF membrane (0.2μmp o r es i z e ,
Immobilon-PSQ, Millipore). Then, the membranes were
blocked in TBS-T (TBS containing 0.01% Tween-20) with
2% blocking regent (ECL Advance Blocking Agent, GE
Healthcare)for1houratroomtemperature.Themembranes
were then incubated with anti-APP C-termini antibody
APP(C) (1μg/mL, IBL), anti-soluble α-cleavage APP frag-
ment (sAPPα,5μg/mL, IBL), anti-soluble β-cleavage APP-
swe fragment (sAPPβsw, 5μg/mL, IBL), and anti-GAPDH
antibody (0.1μg/mL, AbD Serotec) for 1 hour at room
temperature, before being washed with TBS-T and treated
with the secondary antibody (1 hour). The anti-sAPPα
and sAPPβ antibodies exclusively detect only human sAPPα
and sAPPβsw, respectively, but are not reactive to APP
full length. Development was performed with enhanced
chemiluminescence reagent (ECL plus, GE Healthcare) and
detected using an LAS-3000 Mini (Fujiﬁlm).
2.6. Antibodies. The antibodies used were anti-Aβ42;
1:2,000 (IBL, No. 18582), anti-Aβ40; 1:2,000 (IBL, No.
18580), anti-Aβ(N); 1:2,000 (IBL, No. 10323, clone 82E1),
anti-APP(C); 1:100 (IBL, No. 18961), anti-sAPPα;1 : 2 0
(IBL, No. 11088, clone 2B3), anti-sAPPβ;1 : 2 0( I B L ,N o .
10321, clone 6A1) and anti-GAPDH; 1:3,000 (AbD Serotec,
No. 4699-9555, clone 6G5)
2.7. Statistical Analyses. All data are presented as means ±
s.e.m. The diﬀerences among the four groups were analyzed
with one-way analysis of variance (ANOVA) followed by
Bonferroni’s test, and P values of <.05 or <.01 on the
unpaired T-test or Welch’s test were considered statistically
signiﬁcant.
3. Results
3.1. Generation of PS2 (N141I) and Tg2576 Double Transgenic
Mice (PS2Tg2576). We crossbred a Tg2576 mouse with PS2
(N141I) mutant mice to generate double transgenic mice.
The PS2Tg2576 mutant mice were born at the expected
Mendelian ratio in males (23.0%) and females (28.1%) and
grew without morphological abnormalities. Of the male
mice, three mutant mice showed a signiﬁcantly low body
weight compared to the wild-type mice (Supplementary
Figure 1(a) available online on doi: 10.1155/2011/617974).
In the female mice, the PS2Tg2576 and Tg2576 mice
exhibited a signiﬁcantly low body weight compared to
the wild-type and PS2 mice (Supplementary Figure 1(b)).
However, we failed to detect any diﬀerences in food intake
(Supplementary Figure 2(a)), drinking water (Supplemen-
tary Figure 2(b)), or metabolic parameters (Supplementary
Figures 2(c) and 2(d)) among the mutant mice.
3.2. Early Onset of Amyloid Deposition Accompanied by Insol-
uble Aβ Hyperaccumulation in the Brains of the PS2Tg2576
Mice. To investigate the pathological eﬀect of the familial
PS2 (N141I) mutation on Tg2576 mice, amyloid plaques in
the brain sections of the PS2Tg2576 mice were immunos-
tained with the 82E1 monoclonal antibody against the N-
terminal of Aβ. As shown in Figure 1(a), amyloid depo-
sitions were positively detected in the PS2Tg2576 mice at
2-3 months of age. At 4-5 months, signiﬁcant amyloid
accumulations were observed in the hippocampus and the
cerebral neocortex of the PS2Tg2576 mice (Figure 1(b)).
Interestingly, the levels of typical senile plaques were dra-
matically increased in the PS2Tg2576 mice at 6-7 months of
age(Figure 1(c));incontrast,noplaquesweredetectedinthe
brainsoftheTg2576miceat6-7monthsofage(Figure 1(d)).
Furthermore, the amyloid plaques also immunoreacted with
antibodies against the C-terminus of Aβ42 (Supplementary
Figure 3) or Aβ40 (Supplementary Figure 4), producing
the same staining pattern as seen with the 82E1 antibody.
Next, to quantify the amyloid plaques in the neocortex
and hippocampus, we measured the number of plaques in
the brain sections by densitometric analysis (Table 1 and
Figure 2(a)). The mean plaque number of the PS2Tg2576
mice at 2-3 months of age was 17.7 ± 2.9, and it had
markedly increased at 4-5 months (160.3 ± 4.3) and 6-7
months of age (645.7 ± 98.6). We failed to count any plaques
until 6-7 months of age in the Tg2576, PS2, and wild-type
mice (Table 1 and Figure 2(a)). In addition, the numbers
of Aβ42 and Aβ40 positive-plaques were also increased
in the PS2Tg2576 mice with the same pattern (data not
shown).TheseresultsindicatedthatPS2Tg2576miceshowed
signiﬁcant deposition of robust senile plaques from a young
age (2-3 months of age).
To conﬁrm the results of the immunohistochemical
analyses, we measured the concentration of brain Aβ in4 Journal of Biomedicine and Biotechnology
2-3 months
PS2Tg2576
(a)
4-5 months
PS2Tg2576
(b)
6-7 months
PS2Tg2576
(c)
6-7 months
Tg2576
(d)
Figure 1: Early accumulation of amyloid deposition in the brains of PS2Tg2576 mice. Amyloid plaques were immunoreacted with the 82E1
monoclonal antibody against the N-terminal of Aβ.(a) At 2-3 months of age, typical amyloid plaques were positively detected in PS2Tg2576
mouse brains. (b) At 4-5 months, amyloid depositions were signiﬁcantly observed in the hippocampus and the cerebral neocortex of the
PS2Tg2576 mice. (c) In the 6-7 month-old PS2Tg2576 mice, markedly high levels of typical amyloid plaques were observed. (d) No plaques
were detected in the brains of the Tg2576 mice at 6-7-months of age. The insets show a high magniﬁcation image of the boxed area. The
arrowheads indicate plaques in the PS2Tg2576 mice at 2-3 months of age. The scale bars represent 200μm and 5μm in the main panel and
inset, respectively.
the TBS-insoluble fraction by speciﬁc ELISA (Table 1 and
Figures 2(b) and 2(c)). In agreement with the plaque
numbers, the concentrations of Aβ42 and Aβ40 in the
PS2Tg2576 mice at 2-3 months of age were signiﬁcantly
higher (4.2 ± 0.4 and 2.9 ± 0.3ng/mg protein, resp.) than
those in the Tg2576 mice at the same age (Table 1). At 4-
5 months of age, the concentrations of Aβ42 and Aβ40 in
the PS2Tg2576 mice were dramatically enhanced to 75.2 ±
3.9 and 51.5 ± 4.0ng/mg protein, respectively, (Table 1). At
6-7 months of age, these concentrations in the PS2Tg2576
mice were increased to 411.8 ± 19.0 and 380.1 ± 18.5ng/mg
protein, respectively (Table 1). In contrast, the Tg2576 mice
did not show altered levels of insoluble Aβ from 2-3 to
6-7 months of age. These results indicated that the early
accumulation of insoluble Aβ occurs in PS2Tg2576 mice and
that the insoluble Aβ burden was consistent with the results
oftheimmunohistochemicalanalyses(Figure 2andTable 1).
In the TBS-soluble fraction, no diﬀerence in the levels
of Aβ42 and Aβ40 was detected in the PS2Tg2576 mice
at 2-3 months of age (Table 1). At 4-5 months of age, the
concentration of Aβ42 in the PS2Tg2576 mice was detected
tobe2.9 ±0.6pg/mgprotein(Table 1).At6-7monthsofage,
the concentrations of Aβ42 and Aβ40 in the PS2Tg2576 mice
were signiﬁcantly higher (7.1 ± 0.7 and 151.4 ± 11.8 pg/mgJournal of Biomedicine and Biotechnology 5
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Figure 2: Quantiﬁcation of cerebral amyloid accumulation in PS2Tg2576 mice. (a) Number of amyloid plaques (counts per cross section of
halfbrain ±s.e.m)accordingto82E1antibodystaining(n = 3).ELISAmeasurementofAβ42(b)andAβ40(c)intheTBS-insolublefraction
prepared from whole mouse brains (n = 3–8). The values are expressed as mean ± s.e.m ng per mg of protein. Statistical signiﬁcance was
assessed using the unpaired T-test and Welch’s test: ∗P<. 05 compared with the Tg2576 mice at 2-3 months of age. No other diﬀerences
were found.
protein, resp.) than those in the Tg2576 mice at the same age
(Table 1).
3.3. Acceleration of Spatial Memory Impairment in the Morris
Water Maze. WeusedtheMorriswatermaze[18]toexamine
whether the presence of a PS2 mutant transgene leads to the
exacerbation of spatial learning and memory dysfunctions in
Tg2576 mice. The mouse cohorts with approximately equal
numbers of males and females were repeatedly tested at 4-
5 and 6-7 months of age in a longitudinal study. Males
and females separately had tendencies similar to the gender-
mixed results in the behavioral tests (data not shown). At 4-5
months of age, the latency in each group was approximately
30sec at day 4 (Figure 3(a)). In the probe trial, only the
PS2Tg2576 mice demonstrated a signiﬁcantly low score with
regardtothenumberofcrossingsovertheremoved-platform
as a narrow range analysis (unpaired T-test, P<. 01 versus
Tg2576 mice and P<. 05 versus wild-type mice, Figures
3(b) and 3(d)) and the percentage of time spent in the target
quadrant as a broad range analysis (unpaired T-test, P<. 056 Journal of Biomedicine and Biotechnology
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Figure 3: Morris water maze performed at 4-5 months of age of PS2Tg2576 mice. (a) The escape latency of 4-5-month-old mice in the
hidden platform trial. Training trials were repeated for 4 days (1 minute/trial, 4 trials/day). The graph shows representative swimming paths
of individual mice on day 4 of the training phase. (b) The number of crossings of the removed-platform area in the probe test. A probe
trial, in which the platform was removed, was performed for 2 minutes on the day after the training trials had ﬁnished. (c) Percentage of
time spent in the target quadrant during the probe trial. (d) Representative swimming paths of individual mice during the probe test in
the training phase. The arrowhead represents the entry point. Values represent the mean ± s.e.m. (n = 12-24, female and male mixture).
Statistical signiﬁcance was assessed using the unpaired T-test (c, d): ∗P<. 05 compared with the wild-type mice at the same age; #P<. 05
compared with the Tg2576 mice at the same age.
versus Tg2576 mice and P<. 01 versus wild-type mice,
Figures 3(c) and 3(d)).
At 6-7 months of age, only the PS2Tg2576 mice showed
a signiﬁcant typical delay at day 3 and day 4 on the training
task (one-way ANOVA and unpaired T-test versus wild-type
mice, P<. 01, Figure 4(a)). In contrast, the Tg2576, PS2,
and wild-type mice learned to locate the platform during
training and quickly achieved the goal (Figure 4(a)). In the
probe trial, the PS2Tg2576 mice showed signiﬁcantly lower
scores than the wild-type mice with regard to the number
of crossings (unpaired T-test, P<. 05, Figures 4(b) and
4(d)) and the time spent in the target quadrant (unpaired
T-test, P<. 01, Figures 4(c) and 4(d)). The Tg2576 mice also
showed signiﬁcantly lower scores compared with the wild-
typemicewithregardtothetimespentinthetargetquadrant
(unpaired T-test, P<. 05, Figures 4(c) and 4(d)), indicatingJournal of Biomedicine and Biotechnology 7
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Figure 4: Morris water maze performed at 6-7-months of age using PS2Tg2576 mice. (a) The escape latency of the 6-7 month-old mice in
the hidden platform trial. Training trials were repeated for 4 days (1 minute/trial, 4 trials/day). Only the PS2Tg2576 mice showed signiﬁcant
task errors on days 3 and 4 (using one-way ANOVA, ∗P<. 05). The graph shows representative swimming paths of individual mice on
day 4 of the training phase. (b) The number of crossings of the removed-platform area during the probe test. A probe trial, in which the
platform was removed, was performed for 2 minutes on the day after the training trials had ﬁnished. (c) Percentage of time spent in the
target quadrant during the probe trial. (d) Representative swimming paths of individual mice during the training phase of the probe test.
The arrowhead represents the entry point. Values represent the mean ± s.e.m. (n = 18-24, approximately equal numbers of male and female
mixture). Statistical signiﬁcance was assessed using the unpaired T-test (c, d): ∗P<. 05 compared with the wild-type mice at the same age.
that memory impairment progressed in the Tg2576 mice
according to age as previously described elsewhere [12].
These results indicated that the PS2 (N141I) mutation
signiﬁcantly accelerates Aβ-dependent spatial learning and
memory dysfunction in Tg2576 mice.
Next, we performed other behavioral tests under the
placidity home cage, Y maze, elevated plus maze, and open
ﬁeld protocols, because Tg2576 mice showed abnormal
activities and behaviors even before Aβ deposition [9].
Locomotiveactivitywasmonitoredbyinfraredsensorsinthe
homecage.At6-7monthsofage,theTg2576andPS2Tg2576
mice showed signiﬁcantly higher activity in the dark phase
compared to the PS2 and wild-type mice (Supplementary
Figure 5). The same activities were observed in the Tg2576
and PS2Tg2576 mice at 2-3 and 4-5 months of age (data
not shown). To investigate cognitive function, we analyzed
spontaneous alternation using the Y maze [19]. Our Tg2576
and PS2Tg2576 mice also made fewer alternations in course8 Journal of Biomedicine and Biotechnology
Table 1: Characterization of amyloid accumulation in the mouse brain.
Genotype Age (months)
Number of
plaques (n = 3)
(counts/section)
Insoluble fraction (n = 3–8) Soluble fraction (n = 3–8)
Aβ42 (ng/mg
protein)
Aβ40 (ng/mg
protein)
Aβ42 (pg/mg
protein)
Aβ40 (pg/mg
protein)
wild-type
2-3 ND ND 0.2 ±0.0N D 8 4 .2 ±4.2
4-5 ND ND 0.2 ±0.0N D 8 7 .5 ±7.1
6-7 ND ND 0.3 ±0.0N D 8 7 .1 ±6.3
PS2
2-3 ND ND 0.2 ±0.0N D 6 8 .6 ±4.7
4-5 ND ND 0.2 ±0.0N D 9 3 .8 ±5.3
6-7 ND ND 0.3 ±0.0N D 8 6 .4 ±8.3
Tg2576
2-3 ND 0.7 ±0.22 .1 ±0.1∗ ND 82.5 ±23.0
4-5 ND 0.7 ±0.12 .2 ±0.1∗ ND 83.6 ±5.8
6-7 0.0 ±0.00 .6 ±0.12 .2 ±0.1∗ 3.5 ±1.08 1 .1 ±5.1
PS2Tg2576
2-3 17.7 ±2.94 .2 ±0.4# 2.9 ±0.3∗,# ND 70.7 ±5.1
4-5 160.3 ±4.37 5 .2 ±3.9# 51.5 ±4.0∗,# 2.9 ±0.67 4 .9 ±5.0
6-7 645.7 ±98.6 411.8 ±19.0# 380.1 ±18.5∗,# 7.1 ± 0.7# 151.4 ±11.8∗,#
The concentration of cerebral Aβ42 and Aβ40 in the TBS-insoluble and soluble fractions was measured with speciﬁc ELISA kits. Values represent the mean ±
s.e.m. ND: not detectable. Statistical signiﬁcance was assessed using the unpaired T-test and Welch’s test: ∗P<. 05 compared with the wild-type mice at the
same age; #P<. 05 compared with the Tg2576 mice at the same age.
than the PS2 and wild-type mice from 2-3 months of age
(Supplementary Figure 6). We also assessed anxiety-based
activity using the elevated plus maze task [20]. The elevated
plus maze test showed that the Tg2576 and PS2Tg2576 mice
presented with signiﬁcantly lower scores compared to the
PS2 and wild-type mice with regard to the number of entries
to open arms as well as the percentage of time spent in open
arms (Supplementary Figure 7). Lastly, in the open ﬁeld
exploration[21],weobservednodiﬀerenceamonganyofthe
mice (Supplementary Figure 8). Taken together, these results
indicated that both PS2Tg2576 and Tg2576 mice showed
abnormal behaviors in an Aβ-independent manner from 2-3
months of age.
3.4. Western Blot Analysis of β-Amyloid Precursor Protein
(APP). To investigate whether the PS2 (N141I) mutation
enhances the cleavage of APP in Tg2576 mice, we examined
the levels of APP processing by Western blotting analyses
using antibodies against the C-terminal ends of full-length
APP and soluble APP fragments (Figure 5(a)). The low
molecular weight bands for the APP C-terminal fragments
were consistent with the 13-kDa β-cleavage fragment (β-
CTF) and the 10-kDa α-cleavage fragment (α-CTF) by
their apparent molecular mass (Figure 5(b)). These bands
were slightly increased in the brain extracts of PS2Tg2576
compared with Tg2576 mice. To conﬁrm the enhancement
of α-a n dβ-cleavages of APP in the PS2Tg2576 mouse
brains, we next examined the levels of APP N-terminus
fragments (sAPP) by a Western blotting analysis using anti-
sAPPα and sAPPβ antibodies. These antibodies speciﬁcally
recognize the C-terminus of human sAPPα and sAPPβ,
respectively. The bands corresponding to sAPPα and sAPPβ
were observed in the Tg2576 and PS2Tg2576 mice (Figures
5(c) and 5(d)). Both sAPP bands in the PS2Tg2576 mice
were also upregulated compared with those in the Tg2576
mice, indicating that the α-a n dβ-cleavage activities against
APP were upregulated in the PS2Tg2576 mice. In addition,
the APP full-length band was slightly enhanced by the
PS2 mutation in Tg2576 mice (Figure 5(a)), suggesting that
holo-APP proteins were upregulated or stabilized in the
PS2Tg2576 mouse brain. These results suggest that the
hyperaccumulation of cerebral Aβ in the PS2Tg2576 mice
was induced by the modulation of APP processing in the
brains of these mice.
3.5. Life Span of PS2Tg2576 Mice. Survival plots for male
and female mice of each genotype were produced using
Kaplan-Meier survival curves, and statistical signiﬁcance was
calculated using the original method of the log-rank test
(Figure 6). In males, the PS2Tg2576 and Tg2576 mice grad-
ually died from day 70 to day 294, but this was not the case
for the wild-type or PS2 mice, except for accidental deaths
attributedtoﬁghting.Infemales,theTg2576andPS2Tg2576
mice had signiﬁcantly shortened life spans compared with
the wild-type and PS2 mice (P<. 05). At 132 days of age,
the PS2Tg2576 female mice showed a signiﬁcant life span
extension compared with the Tg2576 mice (P<. 05).
4. Discussion
In the present study, we showed that a PS2 mutant acceler-
ated AD-like phenotypes such as Aβ deposition and memoryJournal of Biomedicine and Biotechnology 9
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Figure 5: APP fragments were detected in mouse brains by
Western blot analyses. Ten or twenty micrograms of whole brain
proteins were prepared from each genotype at 10-11 months of
age. (a) Rodent and human APP full-length (APP-FL) and (b) C-
terminal fragments (β-a n dα-CTF) were detected with the anti-
APP C-terminus speciﬁc antibody. (c) The α-cleavage soluble APP
(sAPPα) band was observed with anti-sAPPα C-terminus speciﬁc
antibody. (d) The β-cleavage soluble APP (sAPPβ) band appeared
with anti-sAPPβ C-terminus speciﬁc antibody. (e) Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used as an internal
standard.
impairment. Since the formation of Aβ42 aggregates occurs
faster than that of Aβ40 in vitro and increased Aβ42
production accelerates Aβ accumulation in senile plaques
[22], insoluble Aβ42 hyperaccumulation in PS2Tg2576 mice
(Figure 2(b)) suggests that Aβ42 hyperproduction induces
plaque formation in the brain. It has been reported that
the PS2 (N141I) mutation upregulates the ratio of Aβ42
to Aβ40 by abnormal γ-secretase activity in cultured cells
and transgenic mice [23, 24]. Unexpectedly, the PS2Tg2576
miceshowedenhancementofbothAβ42andAβ40including
sAPPβ as well as β-CTF (Figures 2(b) and 2(c),a n dTable 1),
indicating the modiﬁcation of APP processing, such as γ-
and β-cleavage. In addition, the PS2Tg2576 mice showed
increased holo-APP protein expression (Figure 5(a)), sug-
gesting that the PS2 mutation upregulates or stabilizes APP
proteins, leading to enhancement of APP processing with
increased substrate availability. Interestingly, the PS2Tg2576
mice also exhibited the modiﬁcation of α-cleavage of APP,
suchassAPPαandα-CTF(Figures5(b)and5(c)),suggesting
that increased substrate availability of APP induced the
upregulation of α-cleavage. Further studies are needed to
clarify the molecular mechanism underlying the α-a n dβ-
cleavage activation and APP upregulation or stabilization
induced by the PS2 mutation.
Next, we focused on whether early spatial learning and
memory disorders were accelerated in PS2Tg2576 mice.
Although errors were generally seen in the water maze
task in the Tg2576 mice without amyloid plaques at 6
months of age [12], the PS2 mutation accelerated error-
prone exploration by at least 2 months in the Tg2576 mice
(Figures 3 and 4). Since amyloid plaque hyper-deposition
wasobservedat4-5monthsofage,weconsiderthatinsoluble
Aβ hyperaccumulation induced early memory impairment
in the PS2Tg2576 mice.
Recently, Saura reported that leukocytes and inﬂamma-
tory mediators were elevated in the sera of PS conditional
double knockout mice on an AD model background, sug-
gesting that genetic inactivation of PS conferred neuronal
impairments caused by the inﬂammatory reaction [25].
De Strooper also reported that FAD-linked PS1 or PS2
mutations, including PS2 (N141I), altered the APP cleavage
pattern, leading to an increase of a β-CTF stubble while
therewasadecreaseintheAPPintracellulardomain(AICD),
Notch intracellular domain (NICD), and ErbB4 intracellular
domain (EICD) [26]. Although we failed to detect the AICD
band by an anti-APP C-terminal antibody (Figure 5(b)),
the depletion of ICDs caused by the PS2 mutation might
accelerate neuronal impairments due to the inﬂammatory
response via intracellular signaling through AICD, Notch, or
ErbB4 in Tg2576 mice.
Intriguingly, the PS2Tg2576 mice also exhibited earlier
onset of AD-like phenotypes compared to those of the
PS1Tg2576 [13]o rP S 2 A P P[ 28] double transgenic mice,
whichwereothermodelsofpresenilinandAPPdoubletrans-
genicmice.Furthermore,previousreportsofPS1Tg2576and
PS2APP mice also suggest that the onset of plaque formation
(at 5 and 6 months of age, resp.) was present before the task
errors in the water maze occurred at 8 and 15-16 months of
age, respectively, (Table 2). Although we cannot explain why10 Journal of Biomedicine and Biotechnology
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Figure 6: Kaplan-Meier survival curves of the PS2Tg2576 mice. (a) Survival plots for male mice (wild-type n = 20, PS2 n = 12, Tg2576
n = 18,PS2Tg2576 n = 18). (b)Survival plotsforfemale mice (wild-type n = 16,PS2n = 21,Tg2576n = 12,PS2Tg2576 n = 21).Statistical
signiﬁcance was assessed using the original method of the log-rank test: ∗P<. 05, PS2Tg2576 versus Tg2576 mice at the same age.
Table 2: Comparison of AD-like phenotypes in transgenic mouse models.
Mouse model Genetic background Transgenes Plaque onset∗ Memory impair# Ref.
Tg2576 FVB/N Prion promoted-APPswe
(K670N, M671L)
7-8 6 [9, 12]
PS1Tg2576 Unknown
PDGF ¶promoted-PS1
(M146L) × Prion promoted-
APPswe
6 15-16 [13, 27]
PS2APP B6D2F1 Prion promoted-PS2 (N141I)
× thy1 promoted-APPswe
58 [ 28]
PS2Tg2576 B6 × 129S6
CAG† promoted-PS2
(N141I)× Prion promoted-
APPswe
2-3 4-5 This article
∗Month of age. Previous reported onset of typical amyloid deposition. #Month of age. Previous reports of spatial learning and memory impairment in the
Morris water maze. ¶PDGF, platelet-derived growth factor promoter. †CAG, cytomegalovirus early enhancer coupled with chicken β-actin promoter.
the PS2Tg2576 mice showed earlier onset of amyloid for-
mation and memory impairment compared to PS1Tg2576
and PS2APP mice, some genetic modiﬁers might aﬀect Aβ
metabolism and memory function in PS2Tg2576 mice.
Interestingly, the levels of insoluble Aβ42 and Aβ40 in
the brains of the PS2Tg2576 mice at 4-5 months of age were
consistent with the values observed in a human FAD patient
with the PS2 (N141I) mutation (Table 1). The values of these
factors observed in an FAD patient with the PS2 (N141I)
mutation were 6.7 and 1.5ng/mg wet weight, respectively,
in a previous paper by Maarouf et al. [29]. When the
concentrations of Aβ42 and Aβ40 in the PS2Tg2576 mice
at 4-5 months of age were converted to ng per mg wet
weight of mouse brain, they were found to have values of
1.9 ± 0.1 and 1.3 ± 0.1ng/mg wet weight, respectively.
The insoluble Aβ burden in the PS2Tg2576 mouse brain
was therefore consistent with that found in an FAD case
involvingaPS2(N141I)mutation.Thisdatasuggeststhatthe
AD-like pathology of PS2Tg2576 mice is similar to human
FAD pathology. Recently, noninvasive methods of visual-
izing amyloid depositions in human brains using positron
emission tomography have been developed [30]. Imaging
agents against amyloid ﬁbrils such as N-11C methyl-2-(4 -
methylaminophenyl)-6-hydroxybenzothiazole(11C-PIB)can
be detected in typical AD patients and model mice [31]. By
applying this in vivo imaging system to our PS2Tg2576 mice,
we would be able to validate interventional protocols such as
amyloid-lowering therapies.
5. Conclusions
In conclusion, we have demonstrated that PS2Tg2576 mice
consistently develop an early-onset and rapidly progressive
AD-likecerebralβ-amyloidosis.WehavealsoshownthatPS2
mutation induces early insoluble amyloid accumulation and
memory impairment in Tg2576 mice, a mouse model of AD.
Based on the phenotypic characteristics of the mouse line,
we suggest that PS2Tg2576 is a suitable mouse model forJournal of Biomedicine and Biotechnology 11
studying amyloid-lowering therapies and presumably also
for validating new target candidates.
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